Phase II Trial Assessing Efficacy and Toxicity of Capecitabine and Oxaliplatin in the Treatment of Colorectal Cancer

Inclusion Criteria: * Age \>18 * Histologically proven colorectal adenocarcinoma, requiring therapy as defined by one of the four treatment subgroups * No previous malignant disease other than non-melanotic skin cancer or carcinoma-in-situ of the uterine cervix. * Unidimensional measurable disease as assessed by CT. (Unless adjuvant therapy only) * Adequate bone marrow function; Hb \>10g/dl, platelets \>100 x109/l, WBC \>3x109/l, Neut \>1.5x109/l. * Adequate liver function: Serum Bilirubin \<1.5 x upper limit of institutional normal * Adequate renal function, calculated Creatinine Clearance \>50mls/min * No concurrent uncontrolled medical conditions * WHO performance status 0,1 or 2 * Adequate contraceptive precautions, if appropriate * Informed written consent * Negative pregnancy test in women of child bearing age * Life expectancy \> 3 months Exclusion Criteria: * Medical or psychiatric condition that comprise the patient's ability to take informed consent. * Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmia even if controlled with medication) or myocardial infarction within the last 12 months. * Patients with any significant symptoms or history of peripheral neuropathy.